State of Alaska Department of Revenue Has $513,000 Stock Position in Bruker Corporation $BRKR

State of Alaska Department of Revenue trimmed its position in Bruker Corporation (NASDAQ:BRKR) by 3.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,469 shares of the medical research company’s stock after selling 480 shares during the quarter. State of Alaska Department of Revenue’s holdings in Bruker were worth $513,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BRKR. Sculptor Capital LP boosted its holdings in shares of Bruker by 51.6% in the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock worth $108,459,000 after buying an additional 884,423 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after buying an additional 758,301 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Bruker by 65.9% during the first quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company’s stock worth $60,688,000 after purchasing an additional 586,516 shares during the period. Nuveen LLC acquired a new stake in shares of Bruker during the first quarter worth approximately $20,764,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Bruker during the first quarter worth approximately $19,369,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director owned 18,016 shares of the company’s stock, valued at $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 27.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research reports. Bank of America decreased their price target on shares of Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Barclays decreased their price target on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Wells Fargo & Company decreased their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a “buy” rating in a report on Monday, August 4th. Finally, Citigroup decreased their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $51.00.

Bruker Price Performance

Shares of BRKR opened at $34.63 on Thursday. The firm has a market cap of $5.25 billion, a PE ratio of 66.60, a PEG ratio of 4.81 and a beta of 1.20. The firm’s 50 day moving average price is $33.08 and its 200 day moving average price is $37.31. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $65.56.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period in the prior year, the business earned $0.52 EPS. The company’s revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were given a $0.05 dividend. The ex-dividend date of this dividend was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s dividend payout ratio (DPR) is currently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.